$SMMT
Summit Therapeutics Inc. Stock $smmt

$smmt Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000159929823000034 Filed on March 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$705.0K
YoY Change	-100.0%	-100.0%	-61.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.940M	$7.578M	$26.74M
YoY Change	4.22%	-2.6%	13.27%
% of Gross Profit
Research & Development	$9.883M	$5.386M	$52.00M
YoY Change	-51.92%	-76.69%	-39.08%
% of Gross Profit
Depreciation & Amortization	$90.00K	$305.0K	$349.0K
YoY Change	30.43%	-7.01%	5.76%
% of Gross Profit
Operating Expenses	$537.7M	$11.83M	$87.21M
YoY Change	1875.89%	-55.01%	-19.96%
Operating Profit	-$537.2M		-$72.09M
YoY Change	2324.2%		-16.36%
Interest Expense	$8.327M	-$8.076M	$4.401M
YoY Change	-5578.29%	264.44%	1466.19%
% of Operating Profit
Other Income/Expense, Net	-$5.222M	$9.146M	-$6.693M
YoY Change	-786.2%	685.74%	177.03%
Pretax Income	-$542.4M	-$19.23M	-$78.78M
YoY Change	2434.82%	-29.04%	-11.08%
Income Tax
% Of Pretax Income
Net Earnings	-$542.4M	-$19.23M	-$78.78M
YoY Change	2434.82%	-29.04%	-11.08%
Net Earnings / Revenue			-11174.75%
Basic Earnings Per Share	-$1.43		-$0.41
Diluted Earnings Per Share	-$1.43	-$0.10	-$0.41
COMMON SHARES
Basic Shares Outstanding	697.7M shares	201.3M shares	193.3M shares
Diluted Shares Outstanding	378.2M shares		193.3M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$241.9M	$348.6M	$348.6M
YoY Change	212.37%	385.59%	385.59%
Cash & Equivalents	$70.97M	$348.6M	$348.6M
Short-Term Investments	$171.0M
Other Short-Term Assets	$409.0K	$486.0K	$302.0M
YoY Change	-72.27%	-59.53%	3511.46%
Inventory
Prepaid Expenses	$1.186M	$1.504M
Receivables	$0.00	$349.0K	$349.0K
Other Receivables	$4.500M	$5.766M	$5.766M
Total Short-Term Assets	$248.0M	$656.7M	$656.7M
YoY Change	149.44%	574.85%	574.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$412.0K	$906.0K	$5.081M
YoY Change	-57.31%	30.55%	45.84%
Goodwill	$1.839M	$1.798M
YoY Change	-5.84%	-10.5%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$156.0K	$577.0K	$577.0K
YoY Change	-6.02%	239.41%	239.41%
Total Long-Term Assets	$6.870M	$7.456M	$7.456M
YoY Change	-59.68%	-53.58%	-53.58%
TOTAL ASSETS
Total Short-Term Assets	$248.0M	$656.7M	$656.7M
Total Long-Term Assets	$6.870M	$7.456M	$7.456M
Total Assets	$254.9M	$664.2M	$664.2M
YoY Change	118.85%	485.82%	485.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$710.0K	$355.0K	$355.0K
YoY Change	-89.8%	-91.88%	-91.88%
Accrued Expenses	$12.30M	$10.66M	$18.00M
YoY Change	62.56%	48.17%	44.97%
Deferred Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Short-Term Debt	$0.00	$19.77M	$19.77M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.44M	$38.78M	$38.78M
YoY Change	-23.24%	51.36%	51.36%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0M	$494.5M	$494.5M
YoY Change	299.12%
Other Long-Term Liabilities	$1.481M	$1.429M	$4.192M
YoY Change	-46.17%	-48.52%	-6.16%
Total Long-Term Liabilities	$1.481M	$1.429M	$498.7M
YoY Change	-46.17%	-48.52%	11064.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.44M	$38.78M	$38.78M
Total Long-Term Liabilities	$1.481M	$1.429M	$498.7M
Total Liabilities	$121.4M	$537.5M	$537.5M
YoY Change	133.2%	1686.35%	1686.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$920.7M	-$378.3M
YoY Change	186.87%	26.3%
Common Stock	$6.976M	$2.110M
YoY Change	611.11%	115.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$133.5M	$126.7M	$126.7M
YoY Change
Total Liabilities & Shareholders Equity	$254.9M	$664.2M	$664.2M
YoY Change	118.85%	485.82%	485.82%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$542.4M	-$19.23M	-$78.78M
YoY Change	2434.82%	-29.04%	-11.08%
Depreciation, Depletion And Amortization	$90.00K	$305.0K	$349.0K
YoY Change	30.43%	-7.01%	5.76%
Cash From Operating Activities	-$13.13M	$5.191M	-$41.58M
YoY Change	-30.89%	-156.55%	-42.71%
INVESTING ACTIVITIES
Capital Expenditures	$53.00K	-$10.00K	$624.0K
YoY Change	-85.32%	-91.67%	103.92%
Acquisitions
YoY Change
Other Investing Activities	-$645.0M
YoY Change
Cash From Investing Activities	-$645.1M	$10.00K	-$624.0K
YoY Change	178587.81%	-108.33%	103.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$100.0M
YoY Change			33.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$80.11M	520.1M	$620.2M
YoY Change	218.07%	41141.87%	696.04%
NET CHANGE
Cash From Operating Activities	-$13.13M	5.191M	-$41.58M
Cash From Investing Activities	-$645.1M	10.00K	-$624.0K
Cash From Financing Activities	$80.11M	520.1M	$620.2M
Net Change In Cash	-$577.6M	525.3M	$576.8M
YoY Change	-10307.42%	-6634.72%	10633.46%
FREE CASH FLOW
Cash From Operating Activities	-$13.13M	$5.191M	-$41.58M
Capital Expenditures	$53.00K	-$10.00K	$624.0K
Free Cash Flow	-$13.18M	$5.201M	-$42.21M
YoY Change	-31.91%	-157.41%	-42.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001599298
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#ImpairmentOfIntangibleAssetsExcludingGoodwill
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36866
CY2022	dei	Entity Registrant Name EntityRegistrantName	Summit Therapeutics Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	37-1979717
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2882 Sand Hill Road, Suite 106
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Menlo Park,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94025
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	460-8308
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2022	dei	Trading Symbol TradingSymbol	SMMT
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	25700000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	697685365	shares
CY2022	dei	Auditor Firm AuditorFirmId	238
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	348607000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71791000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	349000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1464000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1504000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7161000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	486000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1201000	usd
CY2022Q4	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	5766000	usd
CY2021Q4	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	15695000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	656712000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	97312000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	906000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	694000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4175000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2790000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1798000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2009000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10399000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	577000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170000	usd
CY2022Q4	us-gaap	Assets Assets	664168000	usd
CY2021Q4	us-gaap	Assets Assets	113374000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	355000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4374000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10664000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7197000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5641000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4125000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1690000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1091000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7939000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	662000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	897000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	19770000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38782000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25623000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2763000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1691000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1429000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2776000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	494540000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Liabilities	537514000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	30090000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	211091425	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	211091425	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98039540	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98039540	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2110000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	980000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	504767000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	384049000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1893000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2197000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378330000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-299548000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126654000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	83284000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	664168000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113374000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	705000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1809000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51999000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85352000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26743000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23611000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	8468000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	87210000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	108963000	usd
CY2022	us-gaap	Other Operating Income OtherOperatingIncome	14416000	usd
CY2021	us-gaap	Other Operating Income OtherOperatingIncome	20968000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-72089000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-86186000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6693000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2416000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-78782000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88602000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-78782000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88602000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	193336063	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	193336063	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131714225	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	131714225	shares
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	304000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1597000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78478000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87005000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	79453000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	159000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	74841000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3088000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12804000	usd
CY2021	smmt	Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty	103000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1597000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88602000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	83284000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	111000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99889000	usd
CY2022	smmt	Stock Issued During Period Value Issued For Related Party Interest StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest	7594000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	399000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11948000	usd
CY2022	smmt	Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty	2018000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	304000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-78782000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126654000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-78782000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88602000	usd
CY2022	smmt	Business Combination Assumed Contingent Liability Remeasurement Gain Loss BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss	1265000	usd
CY2021	smmt	Business Combination Assumed Contingent Liability Remeasurement Gain Loss BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss	0	usd
CY2022	smmt	Interest Expense Income Noncash InterestExpenseIncomeNoncash	4303000	usd
CY2021	smmt	Interest Expense Income Noncash InterestExpenseIncomeNoncash	196000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2614000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-326000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1251000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1108000	usd
CY2022	us-gaap	Depreciation Depreciation	349000	usd
CY2021	us-gaap	Depreciation Depreciation	330000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	914000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1017000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	8468000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11948000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	12804000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-301000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-975000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1138000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-5107000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2345000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-215000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-104000	usd
CY2022	smmt	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-8437000	usd
CY2021	smmt	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	6015000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-7278000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-813000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4132000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1711000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4782000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5075000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1609000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3154000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1099000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1068000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41582000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72587000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	624000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	306000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-624000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-306000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	75000000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	111000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	118000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	545000000	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	110000000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25000000	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	110000000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	44000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	54000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	399000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3088000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	620244000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	77916000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1222000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	351000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	576816000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5374000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71791000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66417000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648607000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71791000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	434000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	85000	usd
CY2022	smmt	Debt Issuance Costs Incurred But Not Yet Paid DebtIssuanceCostsIncurredButNotYetPaid	31000	usd
CY2021	smmt	Debt Issuance Costs Incurred But Not Yet Paid DebtIssuanceCostsIncurredButNotYetPaid	0	usd
CY2022	smmt	Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2021	smmt	Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	41000	usd
CY2022	smmt	Deferred Transaction Costs Incurred During Noncash Or Partial Noncash Transaction DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction	425000	usd
CY2021	smmt	Deferred Transaction Costs Incurred During Noncash Or Partial Noncash Transaction DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2860000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3389000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business and Operations and Recent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Business and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company's pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2022, the Company determined that it would seek partners or a divestiture of ridinilazole, the Company's lead product candidate for treating patients suffering from Clostridioides difficile infection, also known as C. difficile infection, or CDI, as the path forward for the clinical development of the asset. As a result of this determination, the Company discontinued its only active study for ridinilazole, a pediatric clinical trial evaluating ridinilazole for treating adolescent patients with CDI. The Company is currently involved in activities related to closeout of ridinilazole clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2022, the Company entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and its affiliates (“Akeso”) pursuant to which we are partnering with Akeso to in-license its breakthrough bispecific antibody, ivonescimab. Ivonescimab, known as AK112 in China and Australia, and also as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential first-in-class bispecific antibody intending to combine the power of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. Ivonescimab was engineered to bring two well established oncology targeted mechanisms together. Through the License Agreement, the Company obtained the rights to develop and commercialize SMT112 in the United States, Canada, Europe, and Japan. In exchange for these rights, an upfront payment of $500,000 is payable to Akeso, $300,000 of which was payable within the later of 15 days after execution of the License Agreement or upon the earliest date on which the parties have actual knowledge that all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and any comparable extension periods with respect to the transactions contemplated by the License Agreement have expired or been terminated (the “Antitrust Clearance Date”) and $200,000 of which is payable within the later of (i) 90 days after execution of the License Agreement or (ii) the Antitrust Clearance Date. In connection with the first payment, up to 16 million shares of Company common stock may be issued in lieu of cash at Akeso’s election (the “Share Transfer”), with the value of such shares based on the ten (10) day volume-weighted average price for the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3ODkzODlhN2Y5ZTQ5YTU5NGZhZjBkOTU3NWJiNDY3L3NlYzpkNzg5Mzg5YTdmOWU0OWE1OTRmYWYwZDk1NzViYjQ2N18xMjEvZnJhZzo1ZDY3Njc0OGY0YTI0NDYxYmEwNTc3Njk3ZTE4N2FlNy90ZXh0cmVnaW9uOjVkNjc2NzQ4ZjRhMjQ0NjFiYTA1Nzc2OTdlMTg3YWU3XzI5Njg2ODE0MDA5ODU5_ee6b046d-73c1-4e76-ae7b-61257c2f97bd">five</span>-trading day period prior to and the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3ODkzODlhN2Y5ZTQ5YTU5NGZhZjBkOTU3NWJiNDY3L3NlYzpkNzg5Mzg5YTdmOWU0OWE1OTRmYWYwZDk1NzViYjQ2N18xMjEvZnJhZzo1ZDY3Njc0OGY0YTI0NDYxYmEwNTc3Njk3ZTE4N2FlNy90ZXh0cmVnaW9uOjVkNjc2NzQ4ZjRhMjQ0NjFiYTA1Nzc2OTdlMTg3YWU3XzI5Njg2ODE0MDA5ODcz_6562584e-2a8f-49f5-8243-e341be554c29">five</span>-trading day period after the execution of the License Agreement. The total of the upfront payment and potential milestone payments is $5,000,000, as Akeso will be eligible to receive regulatory milestones of up to $1,050,000 and commercial milestones of up to $3,450,000. In addition, Akeso will be eligible to receive low double-digit royalties on net sales. The License Agreement closed on January 17, 2023, and both Akeso and Summit entered into the Common Stock Issuance Agreement (“Issuance Agreement”). Pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive 10 million shares of Company common stock in lieu of cash and was paid $274,900 dollars in cash as the initial upfront payment. The remaining $200,000 amount of the upfront payment was paid on March 6, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the "Note Purchase Agreement"), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000. For further details see Note 17.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2023, the Company held a Special Meeting of Stockholders (the “Shareholder Special Meeting”), whereby the following matters were submitted to a vote of the Company’s stockholders: (i) an amendment to the Company’s Restated Certificate of Incorporation, dated September 18, 2020, as amended on July 27, 2022 (the “Restated Certificate”), to increase the number of authorized shares of common stock by 650,000,000 (from 350,000,000 to 1,000,000,000); and (ii) an amendment to the Restated Certificate to effect, as needed, a reverse stock split of all of the outstanding shares of the Company’s common stock at a ratio in the range of 1-for-5 to 1-for-10.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the matters submitted to a vote of the Company’s stockholders at the Special Meeting was approved by the requisite vote of the Company’s stockholders in accordance with the recommendation of the Company’s Board of Directors. The final decision of whether to proceed with the amendments may be determined by the Company's Board of Directors, in its discretion, at any time prior to January 6, 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Company filed Amendment No. 2 to the Restated Certificate of Incorporation (the “Amendment No. 2”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its common stock by 650,000,000 (from 350,000,000 to 1,000,000,000), which became effective on such date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, the Company commenced its previously announced rights offering ("Rights Offering"). On March 1, 2023, the Company closed the Rights Offering, which was fully subscribed. The Company received aggregate gross proceeds from the Rights Offering of $500,000 from the sale of 476,190,471 shares of our common stock at a price per share of $1.05. Issuance costs associated with the Rights Offering were approximately $500. In connection with the closing of the Rights Offering, $400,000 of the unsecured promissory notes, issued by us to Mr. Duggan, matured and became due and the Company repaid the principal amount and all outstanding accrued interest thereunder using a portion of the proceeds from this Rights Offering.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, $20,000 of the unsecured promissory notes, issued by us to Dr. Zanganeh, matured and the Company repaid the outstanding principal balance.</span></div>
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Use of Estimates <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progression of the COVID-19 pandemic continues to evolve and its enduring impact on the Company's business remains uncertain. Management believes the estimates and assumptions underlying its financial statements are reasonable and supportable based on the information available as of December 31, 2022, however, the extent to which the COVID-19 pandemic impacts the Company's financial results beyond December 31, 2022 will depend on future developments that are highly uncertain and cannot be predicted at this time.</span></div>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-78782000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41582000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378330000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	348607000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000000	usd
CY2022Q4	smmt	Research And Development Tax Credit Receivable ResearchAndDevelopmentTaxCreditReceivable	5766000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	349000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4109000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2135000	usd
CY2022	smmt	Research And Development Tax Credit Cash Rebate Maximum Percentage ResearchAndDevelopmentTaxCreditCashRebateMaximumPercentage	0.333
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	569000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10399000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10399000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7939000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and of Significant Supplier</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company's cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements. </span></div>The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8370000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	2	country
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	5081000	usd
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	3484000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7939000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8939000	usd
CY2022	smmt	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	1397000	usd
CY2021	smmt	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	5443000	usd
CY2022	smmt	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	8790000	usd
CY2021	smmt	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	6438000	usd
CY2022	smmt	Contract With Customer Liability Foreign Currency Translation ContractWithCustomerLiabilityForeignCurrencyTranslation	-546000	usd
CY2021	smmt	Contract With Customer Liability Foreign Currency Translation ContractWithCustomerLiabilityForeignCurrencyTranslation	-5000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7939000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7939000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	4523000	usd
CY2021	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	15206000	usd
CY2022	us-gaap	Other Operating Income OtherOperatingIncome	14416000	usd
CY2021	us-gaap	Other Operating Income OtherOperatingIncome	20968000	usd
CY2022Q4	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	5766000	usd
CY2021Q4	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	15695000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4109000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2135000	usd
CY2022	us-gaap	Interest Expense InterestExpense	4401000	usd
CY2021	us-gaap	Interest Expense InterestExpense	242000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1513000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	304000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-39000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6693000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2416000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-46868000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-72244000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-31914000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-16358000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-78782000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88602000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52948000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	49422000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1723000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	941000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3879000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2560000	usd
CY2022Q4	smmt	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	3553000	usd
CY2021Q4	smmt	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2139000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1477000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	64242000	usd
CY2022Q4	smmt	Research And Development Expense Capitalized Amount ResearchAndDevelopmentExpenseCapitalizedAmount	14830000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	54400000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2600000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	226000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	54000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	226000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2654000	usd
CY2022Q4	smmt	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	64016000	usd
CY2021Q4	smmt	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	51746000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	64016000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51746000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	64242000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	54400000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12270000	usd
CY2022Q4	smmt	Research And Development Expense Amortizable Amount ResearchAndDevelopmentExpenseAmortizableAmount	13347000	usd
CY2021	smmt	Deferred Tax Assets Net Increase Decrease Due To Change In Enacted Tax Rate Amount DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount	9311000	usd
CY2021	smmt	Valuation Allowance Deferred Tax Asset Increase Decrease Due To Change In Enacted Tax Rate Amount ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount	9311000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.168
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.105
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.004
CY2022	smmt	Effective Income Tax Rate Reconciliation Tax Credit Refundable Research Percent EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent	0.036
CY2021	smmt	Effective Income Tax Rate Reconciliation Tax Credit Refundable Research Percent EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent	0.083
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.021
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.022
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.016
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	4523000	usd
CY2021	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	15206000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-78782000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88602000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	193336063	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	131714225	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	193336063	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131714225	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25526971	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19820738	shares
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1798000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2009000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	17864000	usd
CY2022Q4	smmt	Finite Lived Intangible Assets Accumulated Amortization And Impairment FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment	17864000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19963000	usd
CY2021Q4	smmt	Finite Lived Intangible Assets Accumulated Amortization And Impairment FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment	9564000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10399000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	914000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1017000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	286513000	usd
CY2022Q4	us-gaap	Cash Cash	62094000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q4	us-gaap	Cash Cash	71791000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2203000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1730000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1297000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1036000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	906000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	694000	usd
CY2022	us-gaap	Depreciation Depreciation	349000	usd
CY2021	us-gaap	Depreciation Depreciation	330000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	164000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	31000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	278000	usd
CY2022Q4	smmt	Research And Development Prepaid Expenses Current ResearchAndDevelopmentPrepaidExpensesCurrent	442000	usd
CY2021Q4	smmt	Research And Development Prepaid Expenses Current ResearchAndDevelopmentPrepaidExpensesCurrent	6138000	usd
CY2022Q4	smmt	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	8911000	usd
CY2021Q4	smmt	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	5226000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2860000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4175000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2790000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1384000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	785000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	137000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1552000	usd
CY2021	us-gaap	Lease Cost LeaseCost	1227000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.025
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1092000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1041000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1474000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1502000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1533000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	381000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4890000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	437000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4453000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1690000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2763000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4453000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	smmt	Business Combination Assumed Contingent Liability Noncurrent BusinessCombinationAssumedContingentLiabilityNoncurrent	1209000	usd
CY2021Q4	smmt	Business Combination Assumed Contingent Liability Noncurrent BusinessCombinationAssumedContingentLiabilityNoncurrent	2531000	usd
CY2022	smmt	Business Combination Assumed Contingent Liability Remeasurement Gain Loss BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss	1265000	usd
CY2021	smmt	Business Combination Assumed Contingent Liability Remeasurement Gain Loss BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss	0	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5821137	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5821137	shares
CY2022Q3	smmt	Common Stock Shares Authorized Increase Decrease CommonStockSharesAuthorizedIncreaseDecrease	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13797556	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.55
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	712000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9837797	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.31
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4097040	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.89
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	61954	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.04
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19476359	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.55
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29657000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13110654	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.49
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11799000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3895109	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.91
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1652000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.87
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.50
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	142000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3744000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9250000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11948000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12804000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	0	usd
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	0	usd
CY2022Q4	us-gaap	Other Commitment OtherCommitment	11510000	usd
CY2022Q4	smmt	Other Commitment Period For Which The Majority Of Commitments Are To Be Paid OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid	P1Y
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01

Files In Submission

Name	View Source	Status
smmt-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
smmt-20221231_def.xml	Edgar Link	unprocessable
0001599298-23-000034-index-headers.html	Edgar Link	pending
0001599298-23-000034-index.html	Edgar Link	pending
0001599298-23-000034.txt	Edgar Link	pending
0001599298-23-000034-xbrl.zip	Edgar Link	pending
amd1tosublease.htm	Edgar Link	pending
amd1tosublease001.jpg	Edgar Link	pending
amd1tosublease002.jpg	Edgar Link	pending
amd1tosublease003.jpg	Edgar Link	pending
amd1tosublease004.jpg	Edgar Link	pending
amd1tosublease005.jpg	Edgar Link	pending
amd2tosublease.htm	Edgar Link	pending
amd2tosublease001.jpg	Edgar Link	pending
amd2tosublease002.jpg	Edgar Link	pending
amd2tosublease003.jpg	Edgar Link	pending
amd2tosublease004.jpg	Edgar Link	pending
amd2tosublease005.jpg	Edgar Link	pending
amd2tosublease006.jpg	Edgar Link	pending
amd2tosublease007.jpg	Edgar Link	pending
amendedandrestated2020st.htm	Edgar Link	pending
amendedandrestated2020st001.jpg	Edgar Link	pending
amendedandrestated2020st002.jpg	Edgar Link	pending
amendedandrestated2020st003.jpg	Edgar Link	pending
amendedandrestated2020st004.jpg	Edgar Link	pending
amendedandrestated2020st005.jpg	Edgar Link	pending
amendedandrestated2020st006.jpg	Edgar Link	pending
amendedandrestated2020st007.jpg	Edgar Link	pending
amendedandrestated2020st008.jpg	Edgar Link	pending
amendedandrestated2020st009.jpg	Edgar Link	pending
amendedandrestated2020st010.jpg	Edgar Link	pending
executedofferdocuments-a.htm	Edgar Link	pending
executedofferdocuments-a001.jpg	Edgar Link	pending
executedofferdocuments-a002.jpg	Edgar Link	pending
executedofferdocuments-a003.jpg	Edgar Link	pending
executedofferdocuments-a004.jpg	Edgar Link	pending
executedofferdocuments-a005.jpg	Edgar Link	pending
executedofferdocuments-a006.jpg	Edgar Link	pending
executedofferdocuments-a007.jpg	Edgar Link	pending
executedofferdocuments-a008.jpg	Edgar Link	pending
executedofferdocuments-a009.jpg	Edgar Link	pending
executedofferdocuments-a010.jpg	Edgar Link	pending
executedofferdocuments-a011.jpg	Edgar Link	pending
executedofferdocuments-a012.jpg	Edgar Link	pending
executedofferdocuments-a013.jpg	Edgar Link	pending
executedofferdocuments-a014.jpg	Edgar Link	pending
executedofferdocuments-a015.jpg	Edgar Link	pending
executedofferdocuments-a016.jpg	Edgar Link	pending
executedofferdocuments-a017.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smmt-20221231.htm	Edgar Link	pending
smmt-20221231.xsd	Edgar Link	pending
smmt-20221231_g1.jpg	Edgar Link	pending
smmt-20221231_g2.jpg	Edgar Link	pending
sum-ex211_20221231xxsubsid.htm	Edgar Link	pending
sum-ex231_20221231xxuscons.htm	Edgar Link	pending
sum-ex311_20221231xduggan.htm	Edgar Link	pending
sum-ex312_20221231xzanganeh.htm	Edgar Link	pending
sum-ex313_20221231xdhingra.htm	Edgar Link	pending
sum-ex321_20221231xx404906.htm	Edgar Link	pending
smmt-20221231_lab.xml	Edgar Link	unprocessable
smmt-20221231_pre.xml	Edgar Link	unprocessable
smmt-20221231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMMT
Summit Therapeutics Inc. Stock $smmt

2023 Q1 Form 10-K Financial Statement

#000159929823000034 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMMT Summit Therapeutics Inc. Stock $smmt

2023 Q1 Form 10-K Financial Statement

#000159929823000034 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMMT
Summit Therapeutics Inc. Stock $smmt